The BioWorld Insider Podcast
Episodes
Finding a better, longer-lasting fix in opioid overdose
10 Dec 2025
Contributed by Lukas
The opioid crisis may not be front and center anymore, but it's raging still. A major problem is that overdose-reversal drugs don't last long enough t...
Esperion Therapeutics CEO Sheldon Koenig
12 Nov 2025
Contributed by Lukas
Starting with the Clear Outcomes study in 2023, which gave Esperion Therapeutics immediate success with more than 1 billion impressions globally, the ...
Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – AUDIO
29 Aug 2025
Contributed by Lukas
Bioxcel Therapeutics Inc.'s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients...
Trying this at home: Bioxcel steps closer to an sNDA for Igalmi – VIDEO
27 Aug 2025
Contributed by Lukas
Bioxcel Therapeutics Inc.'s phase III results in bipolar disorders or schizophrenia could bring Igalmi (BXCL-501) out of the clinic and into patients...
The importance of balancing AI and people in drug development
27 May 2025
Contributed by Lukas
More and more, artificial intelligence is becoming inseparable from drug development. But it needs to be well integrated with the right people and sup...
Two CEOs discuss bracing for tariffs, NIH grant cuts and gifting China biopharma leadership position
23 Apr 2025
Contributed by Lukas
As pharma deals with the impact of NIH grant cuts and what could follow with the imposition of tariffs, Robert Williamson, CEO of Triumvira Immunol...
As biopharma investments stumble, med tech surges
30 Mar 2025
Contributed by Lukas
The biopharma sector is still trying to get its wind and resume its once-powerful investment ways. Medical technology has sidestepped much of biopharm...
Mega money well spent? Mammoth mergers fall short of the dream
24 Feb 2025
Contributed by Lukas
Billion-dollar M&As are commonplace now, but not too long ago they were a rarity. So many have occurred in the past few years, they've become the norm...
Healing the health divide for women
22 Nov 2024
Contributed by Lukas
As a new BioWorld investigative report shows, decades of research excluding women from clinical trials and investment decisions made in male-dominate...
Modifi gets creative on the rocky road to a multibillion-dollar buyout
13 Nov 2024
Contributed by Lukas
Modifi Biosciences Inc. was recently acquired by Merck & Co. Inc. for $30 million up front. Modifi shareholders could receive milestones of up to $1.3...
A quantum leap into the future of drug development
17 Oct 2024
Contributed by Lukas
In the newest BioWorld Insider podcast, Victoria Lipinska, the America's lead for Quantum Innovation Centers at IBM Quantum, talks about the future of...
Gene and cell therapies will propel innovation, says Astellas CCO
07 Oct 2024
Contributed by Lukas
Gene and cell therapies will drive innovation for the next 10 years, Claus Zieler, the chief commercial officer at Astellas Pharma Inc., said in this ...
Capricor's CEO pursues a BLA and talks rare disease
27 Sep 2024
Contributed by Lukas
Capricor Therapeutics Inc. just wrapped up a visit with the U.S. FDA and is prepping to file a BLA in October for its Duchenne muscular dystrophy trea...
The first half of 2024 was strong as M&As and financings dominate
26 Jul 2024
Contributed by Lukas
Karen Carey, BioWorld managing editor and chief analyst, takes a look at the numbers from the first half of 2024. She finds the first six months to be...
The cost of delays in development and sales: It's probably not what you think
17 Jul 2024
Contributed by Lukas
Two costs of developing drug candidates have been upended by new research from the Tufts University School of Medicine's Center for the Study of Drug ...
ASCO preview: ADCs and radiotherapies at the forefront of this year's conference
30 May 2024
Contributed by Lukas
Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm's Bioimpact Equities and Oncology Impact funds, shares her insights into th...
Fibrobiologics walks the unconventional financing path
15 May 2024
Contributed by Lukas
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O'Heeron o...
Back to fundamentals: The latest numbers point to better times
06 May 2024
Contributed by Lukas
BioWorld Managing Editor Karen Carey joins the podcast to talk about the numbers from the first quarter of 2024, along with a look back at some 2023 d...
Mark McKenna storms back with Mirador and eyes the development landscape
23 Apr 2024
Contributed by Lukas
In one of the biggest financings of the year so far, former Prometheus Biosciences Inc. CEO Mark McKenna helped raise $400 million to launch a new com...
Biopharma execs seek to avoid pain points in AI integration
16 Apr 2024
Contributed by Lukas
Because artificial intelligence is such a new technology it comes with a mountain of unknowns. Integrating it into a pharmaceutical company presents a...
Six biopharma executives consider a tough 2023 and are hopeful for a better 2024
11 Dec 2023
Contributed by Lukas
One aspect of 2023 our group of executives completely agreed on: the past year was tough financially. And they all foresee a more vibrant year ahead f...
AI: driving drug development from effective to remarkable
06 Sep 2023
Contributed by Lukas
Google's Scott Penberthy joins the podcast for a visionary discussion that scans the horizon for startling changes artificial intelligence will bring...
The struggle is real: The first half of 2023 was an uphill climb
16 Aug 2023
Contributed by Lukas
Guests Karen Carey, BioWorld's managing editor, and Mike Ward, Clarivate's global head of Life Sciences and Healthcare Thought Leadership, discuss t...
The biosimilars challenge to Humira revs up
20 Jul 2023
Contributed by Lukas
Guests BioWorld Regulatory Editor Mari Serebrov and Tom Newcomer, Samsung Bioepis vice president and head of U.S. market access, discuss the launch of...
Preventing opioid overdoses with a smart patch
05 Jun 2023
Contributed by Lukas
Brad Holden, CEO of Resilient Lifescience, explains how the device works for overdoses as well as other potential applications for this new technology...
Better times ahead for the biopharma sector? Could be, the new numbers say
24 Apr 2023
Contributed by Lukas
Karen Carey, BioWorld's managing editor and senior data analyst, and Tim Shannon, a general partner at Canaan, break down the numbers from first quart...
Radiopharmaceuticals: The next big disrupter?
05 Apr 2023
Contributed by Lukas
BioWorld Staff Writer Tamra Sami talks about the science behind radiopharmaceuticals, the supply chain vulnerabilities, the regulatory landscape, the ...
Cambrian carves out a new niche as it works to keep people from getting sick
21 Feb 2023
Contributed by Lukas
James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience. Hosted on...
Rethinking obesity: Fitness may be more directly linked to health than weight
30 Jan 2023
Contributed by Lukas
BioWorld Science Managing Editor Anette Breindl discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness ...
Looking ahead to 2023: CEOs contemplate the new normal
05 Dec 2022
Contributed by Lukas
Guests Karen Zaderej, CEO of Axogen Inc., Sean Bohen, CEO of Olema Oncology Inc., Rob Ross, the CEO of Surface Oncology Inc., and Rob Etherington, the...
Psychedelic evolution: Mindset Pharma looks to change mental health treatment
21 Sep 2022
Contributed by Lukas
James Lanthier, the CEO of Mindset Pharma Inc., talks about developing next-generation psychedelic medicines to treat neurological and psychiatric dis...
$1B+ biopharma deals keep values afloat, even amid muted volume
08 Sep 2022
Contributed by Lukas
BioWorld Senior Analyst Karen Carey chats about the collision of a volatile economic climate and big biopharma deals. Hosted on Acast. See acast.com/...
Extending the human lifespan
18 Jul 2022
Contributed by Lukas
Extending the human lifespan, a BioWorld special report, examines the companies developing "Fountain of Youth" drugs. In this episode, the writers d...
New therapies vie to change the fatal course of amyotrophic lateral sclerosis
03 Jun 2022
Contributed by Lukas
Executives from Amylyx Pharmaceuticals Inc. and Clene Inc., along with a key Penn State ALS expert, discuss what the future of medicine holds for pati...
Biopharma's correction? 2022 1Q investments are both up and down
02 May 2022
Contributed by Lukas
BioWorld Senior Analyst Karen Carey explores the newest data and where it is leading. Hosted on Acast. See acast.com/privacy for more information.
Who advises the CDC on big COVID decisions?
23 Feb 2022
Contributed by Lukas
Infection control expert William Schaffner of the Vanderbilt University School of Medicine joins to discuss the CDC's Advisory Committee on Immunizati...
Long COVID: Potentially the next public health crisis
14 Feb 2022
Contributed by Lukas
Senior Science Editor Anette Breindl goes in depth about how long COVID-19 emerged and is being defined. Hosted on Acast. See acast.com/privacy for ...
What happens when your inventor is an artificial intelligence?
14 Dec 2021
Contributed by Lukas
Guests Ryan Abbott, a professor of law and medicine, as well as the leader of the Artificial Inventor Project, and Jim Belfiore, senior vice president...
Another record year for biopharma financings bodes well for 2022
09 Dec 2021
Contributed by Lukas
A conversation with Kleanthis Xanthopoulos, a co-founder and executive chairman of Shoreline Biosciences, and Joe Hernandez, CEO and executive chairma...
Aduhelm's hard lessons and what it means for other Alzheimer's drugs
09 Dec 2021
Contributed by Lukas
Insights into the controversial drug come from guests Michael Agadjanyan, president of Nuravax Inc., which is developing antibodies for preventing Alz...
Supply Chain Geeky: Managing through the challenges of COVID-19 with an eye to what's at stake
09 Dec 2021
Contributed by Lukas
Paul Testa, executive vice president for operations and supply chain at Tokyo-based Kyowa Kirin, on the dramatic importance of continuity, reliabilit...
Regulatory Gemish: COVID-19's big impacts on the FDA and beyond
09 Dec 2021
Contributed by Lukas
Peter Pitts, president of the Center for Medicine in the Public Interest, on how government regulation seems like a slow but in actuality moves more q...
Reality check: How did industry develop COVID-19 vaccines and drugs so fast?
26 Oct 2021
Contributed by Lukas
BioWorld Regulatory Editor Mari Serebrov puts the pandemic and the science into perspective. Hosted on Acast. See acast.com/privacy for more informat...
Merck's new COVID-19 pill will save lives, but at what price?
18 Oct 2021
Contributed by Lukas
Joseph Allen, executive director of the Bayh-Dole Coalition, explains how molnupiravir, from Ridgeback Biotherapeutics, and partner Merck & Co. Inc., ...
Newly approved cervical cancer drug Tivdak gives patients a new option
24 Sep 2021
Contributed by Lukas
The approval of antibody-drug conjugate Tivdak (tisotumab vedotin) for treating cervical cancer and the future of Genmab A/S are the subjects with the...
DNA vaccines: a better path to taming the pandemic?
17 Sep 2021
Contributed by Lukas
An in-depth conversation with Lucio Rovati, CEO and chief scientific officer of Italy's Rottapharm Biotech as they tackle the new world of DNA vaccine...
Rising to the COVID-19 challenge, clinical trials evolve
02 Sep 2021
Contributed by Lukas
Laurie Halloran, president and CEO of Boston-based Halloran Consulting, shares her thoughts on the impact of COVID-19 on clinical trials.
A 'Revolution' in drugging the undruggable hits a speed bump but motors on
20 Aug 2021
Contributed by Lukas
Mark Goldsmith, Revolution Medicines Inc. president, CEO and chairman, talks about grappling with RAS mutations. Hosted on Acast. See acast.com/priva...
As dementia cases grow, biomarkers and new therapies key to unlocking treatment
30 Jul 2021
Contributed by Lukas
Howard Fillit, founding executive director and chief science officer at the Alzheimer's Drug Discovery Foundation, shares his insights on the impact ...
As biopharma deals keep pace, M&A volumes languish
09 Jul 2021
Contributed by Lukas
Biopharma deal-making activity, a closely watched marker of industry health, was alive and well in the second quarter. BioWorld Senior Analyst Karen C...
Iteos brings Glaxosmithkline a third checkpoint-targeting antibody in a $2B deal
16 Jun 2021
Contributed by Lukas
Michel Detheux, president and CEO of Iteos Therapeutics Inc., discusses what his company brings GSK in a massive new deal. Hosted on Acast. See a...
Finally, a new medicine for Alzheimer's disease
10 Jun 2021
Contributed by Lukas
Biogen's vice president of global and U.S. medical affairs for Alzheimer's disease offers insight into Aduhelm. Hosted on Acast. See acast.com/privac...
The BioWorld Insider Podcast - trailer
04 Jun 2021
Contributed by Lukas
Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma's dynamic story. Devel...